AMPY

Amplify is a deep-value setup with real warts. On the numbers it screams cheap: $4.00 buys a business earning $1.03 diluted EPS (3.9x P/E), doing $263M of revenue at a 0.6x P/S, with a fortress-lite balance sheet — $0 long-term debt (down 100% YoY), $60.7M cash (up 192%), and $459M of stockholders' equity against just $142M of liabilities (0.31x). Against 41.3M shares that equity is ~$11 of book value per share, so the stock trades near one-third of book. Liquidity is comfortable (current assets $131M vs. $58.1M current liabilities), operating cash flow held up at $49.2M (-4.1%), and FY2025 operating margin was a healthy 29.2%. For a debt-free producer generating cash, the price embeds a lot of pessimism.

The catch is quality and direction. Revenue has fallen four of the last four years — $458M (2022) → $308M → $295M → $263M — a ~43% decline that signals depletion and/or weaker realizations, consistent with the 10-K's disclosure that WTI slid from ~$80 in early 2025 to ~$55 by December. The headline +239% net-income jump to $44M flatters a volatile, commodity-whipped earnings stream (net income swung from -$32M in 2021 to a $393M one-off in 2023 to $12.9M in 2024), so the 3.9x P/E is not a clean, repeatable multiple. FY2025 also absorbed a $42.5M impairment, underscoring that book value itself is exposed to further price-driven writedowns. ROE is a modest 9.6%.